摘要
目的探究放射性粒子植入联合酪氨酸激酶抑制剂治疗晚期非小细胞肺癌的远期疗效。方法选取在2013年3月-2014年12月期间在我院接收治疗的晚期非小细胞肺癌患者(突变阳性且为ⅢB-Ⅳ期的不可通过手术方法切除)52例作为该研究的对象,按照随机数表法分为观察组和对照组,观察组患者26例,选择放射性粒子植入联合酪氨酸激酶抑制剂进行治疗,对照组26例,选择单药酪氨酸激酶抑制剂进行治疗,治疗结束后对不同组患者的临床治疗率、不良反应以及生存率进行比较和分析。结果观察组患者的局部控制率为92.31%,对照组患者的局部控制率为65.38%,组间差异显著,具有统计学的意义(P<0.05);两组患者的有效率组间比较无显著差异,不具有统计学的意义(P>0.05);两组患者的不良反应发生率组间比较无显著差异,不具有统计学的意义(P<0.05),观察组患者出现1例Ⅲ度白细胞脱落,治疗后恢复正常,两组患者均无出现对其他脏器的功能损害;观察组患者的1年生存率为80.76%,对照组患者的1年生存率为61.54%,组间差异显著,具有统计学的意义(P<0.05);观察组患者的2年生存率为65.38%,对照组患者的2年生存率为38.46%,组间差异显著,具有统计学的意义(P<0.05)。结论酪氨酸激酶抑制剂联合植入放射性粒子治疗晚期非小细胞肺癌疗效优于单用药酪氨酸激酶抑制剂治疗,是一种有效性高、安全性好的治疗方法,值得推广。
Objective To explore the long-term Tfect of radioactive seed implantation combined witli tyro-sine kinase inhibitor in treatment of advanced non small cell lung cancer. Methods From March 2014 in our hospital, 52 advanced non small cell lung cancer patients （ mutation positive and be surgically removed） were randomly divided into the observation group and the （n = 26 ） was given radioactive particles implantation combined witli tyrosine kinase inhibitor treatment, and the control group （ n =26 ） was given single drug of tyrosine kinase inhibitor. After treatment, the curative rate, adverse re-actions and survival rate were compared. Results The local control rate was 92. 31% in the observation group and 65. 38% in the control group （ P 〈 0. 05 ）. There was no significant diference in the efficiency or tile incidence of adverse reactions bet^veen the two groups （ P 〉 0 .0 5 ） . 1 case in the observation group had and was back to normal after treatment, and there was no functional damage to other organs between the two groups.Their 1-year survival rate was 80. 76% in the observation group and 61. 54% in the control group （ P 〈0. 05）. Their 2-year survival rate was 65. 38% in the observation group and 38. 46% in the control group （ P 〈 0. 05 ） . Conclusion The efficacy of tyrosine kinase inhibitor combined witli radioactive particle therapy for advancancer is better than that of single drug tyrosine kinase inhibitor,which is a kind treatment.
出处
《临床肺科杂志》
2018年第3期429-432,共4页
Journal of Clinical Pulmonary Medicine
关键词
放射粒子
酪氨酸激酶抑制剂
非小细胞肺癌
radioactive particles
tyrosine kinase inhibitors
non-small cell lung cancer
